Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Study Details
Study Description
Brief Summary
Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the US Food and Drug Administration for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm A, - Modified DCF Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). |
Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
|
| Active Comparator: ARM B - Parent DCF with G-CSF Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg |
Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17
* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg
Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter.
|
| Active Comparator: Arm C - Modifid DCF + Trastuzumab Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. |
Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
Treatment for Her2 Positive Participants
Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes.
|
Outcome Measures
Primary Outcome Measures
- 6 Month Progression Free Survival (PFS) [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months]
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate
Secondary Outcome Measures
- Overall Survival [From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months]
Overall survival measured in months
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have histologically or cytologically confirmed metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. GEJ adenocarcinoma may be classified according to Siewert's classification type I, II, or III[43].
-
Histological documentation of local recurrence or metastasis is strongly encouraged, unless the risk of such a procedure outweighs the potential benefit of confirming the metastatic disease.
-
If no histologic confirmation, then the metastases or recurrence will require documentation by a 2nd radiographic procedure (eg. PET/CT scan or MRI in addition to the CT scan). If the imaging procedure does not confirm recurrent or metastatic disease, biopsy confirmation will be required.
-
Patients must have disease that can be evaluated radiographically. This may be measurable disease or non-measurable disease. Measurable disease is defined as that which can be measured in at least one dimension as > 20 mm with conventional techniques, or >10 mm by high resolution imaging. Disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurable.
-
Patients may have received no prior chemotherapy for metastatic or unresectable disease. Patients may have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than 6 months have elapsed between the end of adjuvant therapy and registration. Patients may not have received prior docetaxel or cisplatin.
-
Age 18 years or older.
-
Karnofsky performance status > than or = to 70% (ECOG performance status 0-1).
-
Peripheral neuropathy < than or = to grade 1.
-
Hematologic (minimal values):
-
White blood cell count > than or = to 3000/mm3
-
Absolute neutrophil count > than or = to 1500 cells/ mm3
-
Hemoglobin > than or = to 9.0 g/dl
-
Platelet count > than or = to 100,000 / mm3
-
Hepatic (minimal values):
-
Total bilirubin < or = to 1.5
-
- AST and ALT and Alkaline phosphatase must be within the eligible range. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used. Patients with alkaline phosphatase elevation secondary to the bony metastases rather than liver dysfunction may proceed with treatment on protocol after discussion with the principal investigator.
- Kidney function (minimal values):
- Serum creatinine < than or = to 1.5 mg/dl - if serum creatinine is 1.2-1.5 mg/dl, the creatinine clearance (either measured or calculated) must be 50 ml/min or greater
-
The patient has a PT (INR) < than or = to 1.5 and an PTT < than or = to 3 seconds above the upper limits of normal if the patient is not on anticoagulation. If a patient is on full-dose anticoagulants, the following criteria should be met for enrollment:
-
The patient must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of LMW heparin
-
The patient must not have active bleeding or pathological conditions that carry high risk of bleeding (e.g. tumor involving major vessels, known varices)
-
Women of childbearing potential have a negative pregnancy test.
-
Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
-
Ability to understand informed consent and signing of written informed consent document prior to initiation of protocol therapy.
-
Patients must have HER2-positive (FISH+ or IHC 3+) metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma to be eligible for trastuzumab. For the purposes of this protocol, FISH+ is defined as HER2:CEP17 ratio ≥ 2.0. Biopsy samples with cohesive IHC3+ or FISH+ clones are considered HER2 positive irrespective of size, i.e.<10%. FISH+ defined as >2 HER2:CEP17.
-
Patients who are receiving trastuzumab must have a left ventricular ejection fraction of ≥ 50%.
Exclusion Criteria:
-
Patients who have received previous chemotherapy for the treatment of metastatic or unresectable gastric or GEJ adenocarcinoma are ineligible.
-
Patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than 6 months prior to study registration. Patients must have recovered from adverse events from any previous therapy.
-
Patients who have received previous docetaxel or cisplatin.
-
Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer.
-
Patients with brain or central nervous system metastases, including leptomeningeal disease.
-
Pregnant (positive pregnancy test) or breast feeding.
-
Serious, non-healing wound, ulcer, or bone fracture.
-
Significant cardiac disease as defined as:
unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months
-
Evidence of bleeding diathesis or coagulopathy.
-
History of a stroke or CVA within 6 months
-
Clinically significant peripheral vascular disease.
-
Clinically significant hearing loss or ringing in the ears.
-
Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.
-
Inability to comply with study and/or follow-up procedures.
-
Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial.
-
For patients who are Her2 positive and will be treated on the trastuzumab + mDCF cohort, prior trastuzumab treatment is not allowed.
-
For patients who are Her2 positive and will be treated on the trastuzumab+mDCF cohort, left ventricular function <50%
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | City of Hope Cancer Center | Duarte | California | United States | 91010 |
| 2 | Memorial Cancer Institute | Pembroke Pines | Florida | United States | 33025 |
| 3 | Piedmont Hospital Research Institute | Atlanta | Georgia | United States | 30309 |
| 4 | Nebraska Cancer Specialists, Methodist Estabrook Cancer Center | Omaha | Nebraska | United States | 68114 |
| 5 | Memoral Sloan Kettering Cancer Center | Basking Ridge | New Jersey | United States | |
| 6 | Memorial Sloan-Kettering Cancer Center @ Suffolk | Commack | New York | United States | 11725 |
| 7 | Queens Cancer Center of Queens Hospital | Jamaica | New York | United States | 11432 |
| 8 | Long Island Jewish Medical Center | New Hyde Park | New York | United States | 11040 |
| 9 | Weill Medical College of Cornell University | New York | New York | United States | 10021 |
| 10 | Memorial Sloan Kettering Cancer Center 1275 York Avenue | New York | New York | United States | 10065 |
| 11 | Memorial Sloan Kettering at Mercy Medical Center | Rockville Centre | New York | United States | |
| 12 | Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital | Sleepy Hollow | New York | United States | |
| 13 | University Hospital of Cleveland | Cleveland | Ohio | United States | 44106 |
| 14 | University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | United States | 15232 |
| 15 | Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- Memorial Sloan Kettering Cancer Center
- Sanofi
- Roche-Genentech
- City of Hope National Medical Center
- Piedmont Hospital Research Institute
- Medical College of Wisconsin
- Queens Health Network
- Weill Medical College of Cornell University
- Memorial Cancer Institute, Florida
- University of Pittsburgh
- Long Island Jewish Medical Center
- Nebraska Cancer Specialists Methodist Estabrook Cancer Center
Investigators
- Principal Investigator: Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- 06-103
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab |
|---|---|---|---|
| Arm/Group Description | Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). Docetaxel, Leucovorin, Fluorouracil, Cisplatin: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min) | Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter. | Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. |
| Period Title: Overall Study | |||
| STARTED | 54 | 31 | 26 |
| COMPLETED | 54 | 31 | 26 |
| NOT COMPLETED | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab | Total |
|---|---|---|---|---|
| Arm/Group Description | Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). Docetaxel, Leucovorin, Fluorouracil, Cisplatin: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min) | Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter. | Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. | Total of all reporting groups |
| Overall Participants | 54 | 31 | 26 | 111 |
| Age (Count of Participants) | ||||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
40
74.1%
|
23
74.2%
|
24
92.3%
|
87
78.4%
|
| >=65 years |
14
25.9%
|
8
25.8%
|
2
7.7%
|
24
21.6%
|
| Sex: Female, Male (Count of Participants) | ||||
| Female |
14
25.9%
|
9
29%
|
3
11.5%
|
26
23.4%
|
| Male |
40
74.1%
|
22
71%
|
23
88.5%
|
85
76.6%
|
| Race (NIH/OMB) (Count of Participants) | ||||
| American Indian or Alaska Native |
0
0%
|
1
3.2%
|
0
0%
|
1
0.9%
|
| Asian |
5
9.3%
|
1
3.2%
|
2
7.7%
|
8
7.2%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
2
3.7%
|
2
6.5%
|
0
0%
|
4
3.6%
|
| White |
45
83.3%
|
27
87.1%
|
22
84.6%
|
94
84.7%
|
| More than one race |
1
1.9%
|
0
0%
|
0
0%
|
1
0.9%
|
| Unknown or Not Reported |
1
1.9%
|
0
0%
|
2
7.7%
|
3
2.7%
|
| Region of Enrollment (Count of Participants) | ||||
| United States |
54
100%
|
31
100%
|
26
100%
|
111
100%
|
Outcome Measures
| Title | 6 Month Progression Free Survival (PFS) |
|---|---|
| Description | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate |
| Time Frame | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab |
|---|---|---|---|
| Arm/Group Description | Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). Docetaxel, Leucovorin, Fluorouracil, Cisplatin: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min) | Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter. | Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. |
| Measure Participants | 54 | 31 | 26 |
| Mean (95% Confidence Interval) [percentage of paticipants] |
63
|
53
|
73
|
| Title | Overall Survival |
|---|---|
| Description | Overall survival measured in months |
| Time Frame | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab |
|---|---|---|---|
| Arm/Group Description | Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). Docetaxel, Leucovorin, Fluorouracil, Cisplatin: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min) | Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter. | Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. |
| Measure Participants | 54 | 31 | 26 |
| Median (95% Confidence Interval) [months] |
18.8
|
12.6
|
24.9
|
Adverse Events
| Time Frame | 2 years | |||||
|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||
| Arm/Group Title | Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab | |||
| Arm/Group Description | Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments). Docetaxel, Leucovorin, Fluorouracil, Cisplatin: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min) | Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17 * 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter. | Treatment for Her2 Positive Participants Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes. | |||
All Cause Mortality |
||||||
| Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 37/54 (68.5%) | 30/31 (96.8%) | 22/26 (84.6%) | |||
Serious Adverse Events |
||||||
| Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 26/54 (48.1%) | 23/31 (74.2%) | 13/26 (50%) | |||
| Blood and lymphatic system disorders | ||||||
| Blood/Bone Marrow, other | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Febrile neutropenia | 4/54 (7.4%) | 5/31 (16.1%) | 0/26 (0%) | |||
| Hemoglobin | 4/54 (7.4%) | 2/31 (6.5%) | 4/26 (15.4%) | |||
| Hemorrhage/Bleeding, other | 0/54 (0%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Cardiac disorders | ||||||
| Atrial Fibrillation | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Atrial tachycardia/Paroxysmal Atrial Tachycardia | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Cardiac General, other | 0/54 (0%) | 2/31 (6.5%) | 1/26 (3.8%) | |||
| Left ventricular systolic dysfunction | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pain - Cardiac/heart | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Gastrointestinal disorders | ||||||
| Colitis | 1/54 (1.9%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Colitis, infectious | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Constipation | 3/54 (5.6%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Diarrhea | 3/54 (5.6%) | 4/31 (12.9%) | 5/26 (19.2%) | |||
| Distension/bloating, abdominal | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Dysphagia (Difficulty swallowing) | 0/54 (0%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Fistula, GI- Small bowel NOS | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Gastrointestinal, other | 3/54 (5.6%) | 0/31 (0%) | 0/26 (0%) | |||
| Hemorrhage, Stoma (GI) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Hemorrhage, Stomach | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Hemorrhage, Upper GI NOS | 1/54 (1.9%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Ileus, GI (func obstruction of bowel) | 3/54 (5.6%) | 0/31 (0%) | 0/26 (0%) | |||
| Leak, GI- Leak NOS | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Mucositis (Clin exam)- Oral cavity | 1/54 (1.9%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Mucositis (func/sympt)- Oral cavity | 0/54 (0%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Nausea | 8/54 (14.8%) | 9/31 (29%) | 2/26 (7.7%) | |||
| Obstruction, GI- Colon | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Obstruction, GI- Small bowel NOS | 2/54 (3.7%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Obstruction, GI- Stomach | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Abdomen NOS | 8/54 (14.8%) | 6/31 (19.4%) | 1/26 (3.8%) | |||
| Pain - Stomach | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Perforation, GI- Cecum | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Ulcer, Esophagus | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Vomiting | 8/54 (14.8%) | 10/31 (32.3%) | 3/26 (11.5%) | |||
| General disorders | ||||||
| Death not assoc w CTCAE term- Death NOS | 2/54 (3.7%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Death not assoc w CTCAE term-Disease prog NOS | 1/54 (1.9%) | 4/31 (12.9%) | 0/26 (0%) | |||
| Localized Edema - trunk/genital | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Fatigue (asthenia, lethargy, malaise) | 4/54 (7.4%) | 4/31 (12.9%) | 5/26 (19.2%) | |||
| Fever (in the absence of neutropenia) | 2/54 (3.7%) | 0/31 (0%) | 5/26 (19.2%) | |||
| Pain - Other (specify) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Hepatobiliary disorders | ||||||
| Cholecystitis | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Immune system disorders | ||||||
| Allerg react/hypersens (incl drug fever) | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Infections and infestations | ||||||
| Inf norm ANC/gr1/2 neut-Catheter-related | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Inf norm ANC/gr1/2 neut-Urinary(bladder) | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Inf unknown ANC-Abdomen NOS | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Infection w/ Gr 3/4 neut, Lung (pneumonia) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Infection, other | 2/54 (3.7%) | 2/31 (6.5%) | 2/26 (7.7%) | |||
| Injury, poisoning and procedural complications | ||||||
| Wound complication, non-infectious | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Investigations | ||||||
| Creatinine | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| INR | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Leukocytes (total WBC) | 2/54 (3.7%) | 1/31 (3.2%) | 2/26 (7.7%) | |||
| Lymphopenia | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Metabolic/Lab - Other (specify) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Neutrophils/granulocytes (ANC/AGC) | 5/54 (9.3%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Metabolism and nutrition disorders | ||||||
| Anorexia | 2/54 (3.7%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Calcium, low (hypocalcemia) | 0/54 (0%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Dehydration | 5/54 (9.3%) | 7/31 (22.6%) | 4/26 (15.4%) | |||
| Glucose, high (hyperglycemia) | 1/54 (1.9%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Phosphate, low (hypophosphatemia) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Potassium, low (hypokalemia) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Sodium, low (hyponatremia) | 4/54 (7.4%) | 0/31 (0%) | 0/26 (0%) | |||
| Musculoskeletal and connective tissue disorders | ||||||
| Muscle weakness - Right-sided | 1/54 (1.9%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Pain - Back | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Chest wall | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Chest/thorax NOS | 0/54 (0%) | 2/31 (6.5%) | 1/26 (3.8%) | |||
| Pain - Extremity-limb | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Pain - Neck | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Nervous system disorders | ||||||
| CNS cerebrovascular ischemia | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Dizziness | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pain - Head/headache | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Seizure | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Syncope (fainting) | 4/54 (7.4%) | 1/31 (3.2%) | 2/26 (7.7%) | |||
| Respiratory, thoracic and mediastinal disorders | ||||||
| Aspiration | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Cough | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Dyspnea (shortness of breath) | 2/54 (3.7%) | 3/31 (9.7%) | 1/26 (3.8%) | |||
| Pain - Throat/pharynx/larynx | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pneumothorax | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Vascular disorders | ||||||
| Hematoma | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Hypotension | 2/54 (3.7%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Thrombosis/embolism (vascular access-related) | 1/54 (1.9%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Thrombosis/thrombus/embolism | 5/54 (9.3%) | 2/31 (6.5%) | 1/26 (3.8%) | |||
Other (Not Including Serious) Adverse Events |
||||||
| Arm A, - Modified DCF | ARM B - Parent DCF With G-CSF | Arm C - Modified DCF+ Trastuzumab | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 26/54 (48.1%) | 23/31 (74.2%) | 13/26 (50%) | |||
| Blood and lymphatic system disorders | ||||||
| Blood/Bone Marrow, other | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Febrile neutropenia | 4/54 (7.4%) | 5/31 (16.1%) | 0/26 (0%) | |||
| Hemoglobin | 4/54 (7.4%) | 2/31 (6.5%) | 4/26 (15.4%) | |||
| Cardiac disorders | ||||||
| Atrial fibrillation | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Atrial tachycardia/Paroxysmal Atrial Tachycardia | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Cardiac General, other | 0/54 (0%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Left ventricular systolic dysfunction | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pain - Cardiac/heart | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Gastrointestinal disorders | ||||||
| Colitis | 1/54 (1.9%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Constipation | 3/54 (5.6%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Diarrhea | 3/54 (5.6%) | 4/31 (12.9%) | 5/26 (19.2%) | |||
| Distension/bloating, abdominal | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Dysphagia (Difficulty swallowing) | 0/54 (0%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Fistula, GI- Small bowel NOS | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Gastrointestinal, other | 3/54 (5.6%) | 0/31 (0%) | 0/26 (0%) | |||
| Hemorrhage, Stoma (GI) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Hemorrhage, Stomach | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Hemorrhage, Upper GI NOS | 1/54 (1.9%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Ileus, GI (func obstruction of bowel) | 3/54 (5.6%) | 0/31 (0%) | 0/26 (0%) | |||
| Leak, GI- Leak NOS | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Mucositis (Clin exam)- Oral cavity | 1/54 (1.9%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Mucositis (func/sympt)- Oral cavity | 0/54 (0%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Nausea | 8/54 (14.8%) | 9/31 (29%) | 2/26 (7.7%) | |||
| Obstruction, GI- Colon | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Obstruction, GI- Small bowel NOS | 2/54 (3.7%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Obstruction, GI- Stomach | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Abdomen NOS | 8/54 (14.8%) | 6/31 (19.4%) | 1/26 (3.8%) | |||
| Pain - Stomach | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Perforation, GI- Cecum | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Ulcer, Esophagus | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Vomiting | 8/54 (14.8%) | 10/31 (32.3%) | 3/26 (11.5%) | |||
| General disorders | ||||||
| Death not assoc w CTCAE term- Death NOS | 2/54 (3.7%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Death not assoc w CTCAE term-Disease prog NOS | 1/54 (1.9%) | 4/31 (12.9%) | 0/26 (0%) | |||
| Edema: trunk/genital | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Fatigue (asthenia, lethargy, malaise) | 4/54 (7.4%) | 4/31 (12.9%) | 5/26 (19.2%) | |||
| Fever (in the absence of neutropenia) | 2/54 (3.7%) | 0/31 (0%) | 5/26 (19.2%) | |||
| Pain - Other (specify) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Hepatobiliary disorders | ||||||
| Cholecystitis | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Immune system disorders | ||||||
| Allerg react/hypersens (incl drug fever) | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Infections and infestations | ||||||
| Colitis, infectious | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Inf norm ANC/gr1/2 neut-Catheter-related | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Inf norm ANC/gr1/2 neut-Urinary(bladder) | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Inf unknown ANC-Abdomen NOS | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Infection w/ Gr 3/4 neut, Lung (pneumonia) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Infection, other | 2/54 (3.7%) | 2/31 (6.5%) | 2/26 (7.7%) | |||
| Injury, poisoning and procedural complications | ||||||
| Hemorrhage/Bleeding, other | 0/54 (0%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Wound complication, non-infectious | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Investigations | ||||||
| Creatinine | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| INR | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Leukocytes (total WBC) | 2/54 (3.7%) | 1/31 (3.2%) | 2/26 (7.7%) | |||
| Lymphopenia | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Metabolic/Lab - Other (specify) | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Neutrophils/granulocytes (ANC/AGC) | 5/54 (9.3%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Metabolism and nutrition disorders | ||||||
| Anorexia | 2/54 (3.7%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Calcium, low (hypocalcemia) | 0/54 (0%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Dehydration | 5/54 (9.3%) | 7/31 (22.6%) | 4/26 (15.4%) | |||
| Glucose, high (hyperglycemia) | 1/54 (1.9%) | 0/31 (0%) | 2/26 (7.7%) | |||
| Phosphate, low (hypophosphatemia) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Potassium, low (hypokalemia) | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Sodium, low (hyponatremia) | 4/54 (7.4%) | 0/31 (0%) | 0/26 (0%) | |||
| Musculoskeletal and connective tissue disorders | ||||||
| Muscle weakness - Right-sided | 1/54 (1.9%) | 2/31 (6.5%) | 0/26 (0%) | |||
| Pain - Back | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Chest wall | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Pain - Chest/thorax NOS | 0/54 (0%) | 2/31 (6.5%) | 1/26 (3.8%) | |||
| Pain - Extremity-limb | 0/54 (0%) | 1/31 (3.2%) | 1/26 (3.8%) | |||
| Pain - Neck | 2/54 (3.7%) | 0/31 (0%) | 0/26 (0%) | |||
| Nervous system disorders | ||||||
| CNS cerebrovascular ischemia | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Dizziness | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pain - Head/headache | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Seizure | 0/54 (0%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Syncope (fainting) | 4/54 (7.4%) | 1/31 (3.2%) | 2/26 (7.7%) | |||
| Respiratory, thoracic and mediastinal disorders | ||||||
| Aspiration | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Cough | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Dyspnea (shortness of breath) | 2/54 (3.7%) | 3/31 (9.7%) | 1/26 (3.8%) | |||
| Pain - Throat/pharynx/larynx | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Pneumothorax | 0/54 (0%) | 0/31 (0%) | 1/26 (3.8%) | |||
| Vascular disorders | ||||||
| Hematoma | 1/54 (1.9%) | 0/31 (0%) | 0/26 (0%) | |||
| Hypotension | 2/54 (3.7%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Thrombosis/embolism (vascular access-related) | 1/54 (1.9%) | 1/31 (3.2%) | 0/26 (0%) | |||
| Thrombosis/thrombus/embolism | 5/54 (9.3%) | 2/31 (6.5%) | 1/26 (3.8%) | |||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Yelena Janjigian, MD |
|---|---|
| Organization | Memorial Sloan Kettering Cancer Center |
| Phone | 646-888-4186 |
| janjigiy@mskcc.org |
- 06-103